Stock CYBN CYBIN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cybin Inc.

Equities

CYBN

CA23256X1006

Real-time Estimate Cboe BZX
Other stock markets
 11:19:11 2024-06-04 am EDT 		5-day change 1st Jan Change
0.339 USD -1.65% Intraday chart for Cybin Inc. -3.40% -17.56%
May. 06 Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline CI
Apr. 17 Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
BU
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
BU
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
AQ
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones 
BU
Cybin to Participate at the 27th Annual Milken Institute Global Conference
BU
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
BU
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
BU
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
BU
Cybin : MATERIAL CHANGE REPORT - Form 6-K
PU
Cybin : AGENCY AGREEMENT - Form 6-K
PU
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
BU
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
BU
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO
AQ
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
BU
Cybin Inc. - Announces Oversubscribed Private Placement of U.S. $150 Million
AQ
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
BU
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
BU
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
BU
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
BU
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYBN Stock
  4. News Cybin Inc.
  5. Press Releases